Corcept Therapeutics (NASDAQ:CORT) Insider Sells $4,919,250.00 in Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Sean Maduck sold 75,000 shares of the stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $65.59, for a total transaction of $4,919,250.00. Following the completion of the sale, the insider owned 8,977 shares in the company, valued at $588,801.43. This represents a 89.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Corcept Therapeutics Stock Performance

NASDAQ CORT traded up $1.11 on Friday, hitting $69.49. The stock had a trading volume of 774,694 shares, compared to its average volume of 1,782,915. The firm has a 50-day moving average of $47.30 and a 200-day moving average of $52.18. The company has a market capitalization of $7.46 billion, a price-to-earnings ratio of 198.55 and a beta of 0.36. Corcept Therapeutics Incorporated has a 52-week low of $28.66 and a 52-week high of $91.00.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings data on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.19). The company had revenue of $164.90 million for the quarter, compared to analysts’ expectations of $185.83 million. Corcept Therapeutics had a net margin of 6.14% and a return on equity of 7.40%. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.17 EPS. As a group, research analysts anticipate that Corcept Therapeutics Incorporated will post 0.52 earnings per share for the current fiscal year.

Institutional Trading of Corcept Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Pathstone Holdings LLC raised its stake in shares of Corcept Therapeutics by 0.8% in the third quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company’s stock worth $1,497,000 after buying an additional 144 shares during the period. State of Wyoming lifted its position in shares of Corcept Therapeutics by 29.5% during the 1st quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 186 shares in the last quarter. Clearstead Advisors LLC grew its stake in shares of Corcept Therapeutics by 163.6% during the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 193 shares during the period. Gould Capital LLC increased its holdings in Corcept Therapeutics by 50.0% in the 3rd quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 200 shares in the last quarter. Finally, Sequoia Financial Advisors LLC raised its stake in Corcept Therapeutics by 3.7% during the 4th quarter. Sequoia Financial Advisors LLC now owns 6,904 shares of the biotechnology company’s stock worth $240,000 after acquiring an additional 247 shares during the period. Institutional investors own 93.61% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on CORT. Truist Financial upgraded shares of Corcept Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Wolfe Research upgraded shares of Corcept Therapeutics from an “underperform” rating to a “peer perform” rating in a research report on Thursday, March 26th. HC Wainwright boosted their price target on shares of Corcept Therapeutics from $75.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday. Piper Sandler raised their price objective on Corcept Therapeutics from $73.00 to $88.00 and gave the company an “overweight” rating in a research note on Friday, May 1st. Finally, Zacks Research upgraded Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, May 4th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $88.83.

Corcept Therapeutics News Roundup

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Canaccord Genuity raised its price target on Corcept Therapeutics to $135 from $110 and reiterated a buy rating, signaling greater confidence in upside potential. Canaccord Genuity price target update
• Positive Sentiment: HC Wainwright lifted its 2026 earnings estimates for CORT, including higher Q3, Q4, and full-year EPS forecasts, while maintaining a buy rating and $95 target. Higher profit expectations often support the stock. HC Wainwright estimate revisions
• Positive Sentiment: Corcept said it plans to resubmit the NDA for relacorilant in Cushing’s syndrome, which keeps a key pipeline asset alive and appears to be the main business-specific catalyst behind the recent rally. Relacorilant NDA resubmission article
• Neutral Sentiment: Stockholders approved an expanded incentive plan and board-related matters at the 2026 annual meeting; this is supportive of governance but not a major immediate earnings driver. Stockholders approve expanded incentive plan and board

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.